Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ГБУЗ «Городская Покровская больница» 199106 Россия, г. Санкт-Петербург, Васильевский остров, Большой проспект, 85
The choice of antiplatelet and antithrombotic therapy in an elderly patient presenting with stemi during primary PCI (case report)
Список исп. литературыСкрыть список 1. Biostatistical Fact Sheet: Older Americans and Cardiovascular Diseases. Chicago, AHA, 1998. 2. Rich M.W. et al. PRICE-2 Investigators. Am. J. Geriart. Cardiol. 2003;12(5):307–18, 327. 3. Angeja B., Rundle A., Death or nonfatal stroke in patients with acute myocardial infarction. Am. J. Card. 2001 Mar 1;87(5):627-30. 4. Tiefenbrunn A.J. et al. A report from the NRMI -2. J. Am. Coll. Card. 1998;31: 1240. 5. Thiemann D.R., Coresh J., et al.: Lack of benefit for intravenous thrombolysis in patients with MI who are older than 75 years. Сirculation. 2000;101: 2239. 6. Brown D. Deaths associated with platelet glycoprotein IIb/IIIa treatment. Heart. 2003 May;89(5):535–7. 7. ESPRIT Investigators. Lancet. 2000;356:2037–44 8. Fung et al. The Brief-PCI Trial. JACC 53: 2009: 837–45. 9. Gibson C.M., Morrow D.A., Murphy S.A., et al. A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT–TIMI 30 trial. J. Am. Coll. Cardiol. 2006; 47:2364–73. 10. Bertrand O.F. Meta-Analysis Comparing Bivalirudin Versus Heparin Monotherapy on Ischemic and Bleeding Outcomes After Percutaneous Coronary Intervention. Am. J. Cardiol. 2012; 110:599–606. 11. Marso S.P., Amin A.P. Assotiation between of bleeding avoidance strategies and risk of bleeding among patients undergoing PCI. JAMA. 2010 2; 303 (21): 2156–64. 12. Mehran R., Lansky A.J., Witzenbichler B., et al. Bivalirudin in patients undergoing primary angioplasty for acute myocardial in- farction (HORIZONS-AMI): 1-year results of a randomized controlled trial. Lancet. 2009; 374:1149–59. 13. Reduction in Cardiac Mortality With Bivalirudinin Patients With and Without Major Bleeding. Gregg W. Stone et all. J. Am. Coll. Cardiol. 2014;63:15–20. 14. Michael Lincoff A., John A. Bittl. Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade Compared With Heparin and Planned Glycoprotein IIb/IIIa Blockad During Percutaneous Coronary Intervention. REPLACE-2 Randomized Trial. JAMA. 2003 February; 289: 19. 15. Stone G.W., White H.D., Ohman E.M., et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet. 2007; 369:907–19. 16. Лопотовский П.Ю., Пархоменко М.В., Ларин А.Г., Коробенин А.Ю. Применение Бивалирудина В Клинической Практике. Диагностическая и интервенционная радиология. 2012 (6) #4: 79–88. Lopotovskiy P.Yu., Parkhomenko M.V., Larin A.G., Korobenin A.Yu. Primenenie bivalirudina v klinicheskoi praktike. [The use of bivalirudin in clinical practice.] Diagnosticheskaya i intervencionnaya radiologia. 2012 (6) #4: 79–88 [in Russ].